Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Director/PDMR Shareholding
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 10 May 2021, Daniel Lee, Chief Executive Officer, acquired 2,068,750 Ordinary Shares in the Group at a price of 0.69 pence per share for a total consideration of £14,274.38.
As a result, Daniel Lee's beneficial interest in the Company is 2,068,750 Ordinary Shares, representing 0.03% of the total issued share capital.
For more information:
| Tissue Regenix Group plc David Cocke, Chief Financial Officer | Via Walbrook PR |
|
|
|
| Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price | Tel: +44(0)20 7710 7600
|
| Walbrook PR Ltd Alice Woodings / Paul McManus | Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com |
|
|
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.
| 1
| Details of the person discharging managerial responsibilities / person closely associated | |||||||
| a)
| Name | Daniel Lee | ||||||
| 2
| Reason for the notification | |||||||
| a)
| Position/status
| Chief Executive Officer | ||||||
| b)
| Initial notification /Amendment
| Initial notification | ||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a)
| Name
| Tissue Regenix Group plc | ||||||
| b)
| LEI | 213800PNOD5UHQUFJI36 | ||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a)
| Description of the financial instrument, type of instrument
|
Ordinary Shares of 0.1p each
| ||||||
| b) | Identification code
| GB00B5SGVL29 | ||||||
| c)
| Nature of the transaction
| Acquisition of Ordinary Shares | ||||||
| d)
| Price(s) and volume(s) |
| ||||||
| d)
| Aggregated information - Aggregated volume - Price |
2,068,750 £14,274.38 | ||||||
| e)
| Date of the transaction | 10 May 2021 | ||||||
| f)
| Place of the transaction | London Stock Exchange, AIM Market | ||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
